Relates to coverage for treatments to slow the progression of Alzheimer's disease and related dementias

Summary

The bill amends New York’s insurance statutes to require that any medical, major medical, or similar comprehensive policy—whether individual, group, or issued by certain health corporations—cover all medically necessary diagnostic tests and FDA‑approved drugs that aim to slow Alzheimer’s disease and related dementias. Coverage cannot be limited by step‑therapy requirements. The changes take effect on January 1 of the year after the law is enacted and apply to policies issued or renewed thereafter.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share